Mechanistic insights into the dual role of CCAR2/DBC1 in cancer

[1]  Z. Dosztányi,et al.  Acetylation of nuclear receptors in health and disease: an update , 2022, The FEBS journal.

[2]  C. Di,et al.  Mutant p53 in cancer: from molecular mechanism to therapeutic modulation , 2022, Cell Death & Disease.

[3]  H. H. Wu,et al.  DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities , 2022, Experimental & Molecular Medicine.

[4]  S. Basu,et al.  Negative Feedback Loop Mechanism between EAF1/2 and DBC1 in Regulating ELL Stability and Functions , 2022, Molecular and cellular biology.

[5]  Jeong Hoon Kim,et al.  DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300 , 2022, Nucleic acids research.

[6]  S. Yi,et al.  Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation , 2022, Experimental & Molecular Medicine.

[7]  Ja-Eun Kim,et al.  CCAR2 controls mitotic progression through spatiotemporal regulation of Aurora B , 2022, Cell Death & Disease.

[8]  W. Gu,et al.  Deciphering the acetylation code of p53 in transcription regulation and tumor suppression , 2022, Oncogene.

[9]  Hongjuan You,et al.  The interaction of canonical Wnt/β-catenin signaling with protein lysine acetylation , 2022, Cellular & molecular biology letters.

[10]  M. Ghosh,et al.  Chaperone-assisted E3 ligase CHIP: A double agent in cancer , 2021, Genes & diseases.

[11]  S. Ovchinnikov,et al.  ColabFold: making protein folding accessible to all , 2022, Nature Methods.

[12]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[13]  Xiaoling Li,et al.  Trending topics of SIRT1 in tumorigenicity. , 2021, Biochimica et biophysica acta. General subjects.

[14]  C. Allis,et al.  The language of chromatin modification in human cancers , 2021, Nature Reviews Cancer.

[15]  W. Kraus,et al.  Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance , 2021, Experimental & molecular medicine.

[16]  G. Johnson,et al.  CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis , 2020, Cancer science.

[17]  M. Stallcup,et al.  Gene-Specific Actions of Transcriptional Coregulators Facilitate Physiological Plasticity: Evidence for a Physiological Coregulator Code. , 2020, Trends in biochemical sciences.

[18]  Faqing Tang,et al.  Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms , 2020, Experimental & Molecular Medicine.

[19]  S. Mukhopadhyay,et al.  DBC1, p300, HDAC3, and Siah1 coordinately regulate ELL stability and function for expression of its target genes , 2020, Proceedings of the National Academy of Sciences.

[20]  J. Badano,et al.  A novel form of Deleted in breast cancer 1 (DBC1) lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo , 2019, Scientific Reports.

[21]  W. Gu,et al.  p53 modifications: exquisite decorations of the powerful guardian , 2019, Journal of molecular cell biology.

[22]  L. Litovchick,et al.  DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination , 2019, Cell reports.

[23]  J. Liao,et al.  Deleted in Breast Cancer 1 as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis , 2019, Journal of Cancer.

[24]  Ja-Eun Kim,et al.  CCAR2/DBC1 and Hsp60 Positively Regulate Expression of Survivin in Neuroblastoma Cells , 2019, International journal of molecular sciences.

[25]  N. Chen,et al.  The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ERα and enhances ERα target gene expression in breast cancer cells , 2018, Nucleic acids research.

[26]  N. Hannett,et al.  Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains , 2018, Cell.

[27]  Jeong Hoon Kim,et al.  DBC1 regulates Wnt/β-catenin-mediated expression of MACC1, a key regulator of cancer progression, in colon cancer , 2018, Cell Death & Disease.

[28]  Daniel S. Day,et al.  Coactivator condensation at super-enhancers links phase separation and gene control , 2018, Science.

[29]  Jeong Hoon Kim,et al.  DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7 , 2018, Oncogene.

[30]  Zhihai Peng,et al.  Overexpression of DBC1, correlated with poor prognosis, is a potential therapeutic target for hepatocellular carcinoma. , 2017, Biochemical and biophysical research communications.

[31]  K. Ge,et al.  Histone H3 lysine 4 methyltransferase KMT2D. , 2017, Gene.

[32]  S. Armstrong,et al.  A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. , 2017, Molecular cell.

[33]  Lingjun Li,et al.  Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation , 2017, Nucleic acids research.

[34]  Ja-Eun Kim,et al.  Mitochondrial CCAR2/DBC1 is required for cell survival against rotenone-induced mitochondrial stress. , 2017, Biochemical and biophysical research communications.

[35]  Weiqun Peng,et al.  MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis , 2017, Nucleic acids research.

[36]  Kihyun Park,et al.  Writing, erasing and reading histone lysine methylations , 2017, Experimental &Molecular Medicine.

[37]  L. Aravind,et al.  A conserved NAD+ binding pocket that regulates protein-protein interactions during aging , 2017, Science.

[38]  A. Biankin,et al.  Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions , 2016, Oncotarget.

[39]  N. Goshima,et al.  The Sam68 nuclear body is composed of two RNase-sensitive substructures joined by the adaptor HNRNPL , 2016, The Journal of cell biology.

[40]  Jeong Hoon Kim,et al.  Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma. , 2016, Pathology, research and practice.

[41]  H. J. Kim,et al.  Positive regulation of β-catenin–PROX1 signaling axis by DBC1 in colon cancer progression , 2016, Oncogene.

[42]  C. Eng,et al.  Cancer-predisposition gene KLLN maintains pericentric H3K9 trimethylation protecting genomic stability , 2015, Nucleic acids research.

[43]  B. Prabhakar,et al.  Deleted in Breast Cancer 1 Suppresses B Cell Activation through RelB and Is Regulated by IKKα Phosphorylation , 2015, The Journal of Immunology.

[44]  K. Jang,et al.  DBC1/CCAR2 is involved in the stabilization of androgen receptor and the progression of osteosarcoma , 2015, Scientific Reports.

[45]  Guoxin Li,et al.  DBC1 promotes anoikis resistance of gastric cancer cells by regulating NF-κB activity. , 2015, Oncology reports.

[46]  L. Zannini,et al.  CCAR2/DBC1 is required for Chk2-dependent KAP1 phosphorylation and repair of DNA damage , 2015, Oncotarget.

[47]  Tomohiko Fukuda,et al.  CCAR2 negatively regulates nuclear receptor LXRα by competing with SIRT1 deacetylase , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[48]  Charles Y. Lin,et al.  Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.

[49]  K. Jang,et al.  The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma , 2015, Journal of Ovarian Research.

[50]  Liewei Wang,et al.  DBC1 Functions as a Tumor Suppressor by Regulating p53 Stability , 2015, Cell reports.

[51]  H. J. Kim,et al.  A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer , 2014, Oncogene.

[52]  Jong Ho Park,et al.  Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage , 2014, Nature Communications.

[53]  Ja-Eun Kim,et al.  CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells , 2014, Tumor Biology.

[54]  E. Chini,et al.  Deleted in Breast Cancer 1 Limits Adipose Tissue Fat Accumulation and Plays a Key Role in the Development of Metabolic Syndrome Phenotype , 2014, Diabetes.

[55]  Hongwu Zhu,et al.  DBC1 is over-expressed and associated with poor prognosis in colorectal cancer , 2014, International Journal of Clinical Oncology.

[56]  J. Larner,et al.  Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells , 2014, Oncogene.

[57]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[58]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[59]  K. Jang,et al.  Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.

[60]  Yung-Hyun Choi,et al.  Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer , 2013, Korean journal of urology.

[61]  Juan Wang,et al.  The Expression of SIRT1 and DBC1 in Laryngeal and Hypopharyngeal Carcinomas , 2013, PloS one.

[62]  Ja-Eun Kim,et al.  Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of breast cancer cells through impaired responses to UV-induced DNA damage. , 2013, Cancer letters.

[63]  K. Jang,et al.  Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma. , 2013, Translational oncology.

[64]  S. Frisch,et al.  Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-κB , 2013, Apoptosis.

[65]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[66]  M. Ikura,et al.  Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition , 2013, Cellular and Molecular Life Sciences.

[67]  D. Delia,et al.  DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. , 2012, Journal of molecular cell biology.

[68]  Z. Lou,et al.  Regulation of SIRT1 activity by genotoxic stress. , 2012, Genes & development.

[69]  J. Söding,et al.  DBIRD integrates alternative mRNA splicing with RNA polymerase II transcript elongation , 2012, Nature.

[70]  A. Menssen,et al.  The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop , 2011, Proceedings of the National Academy of Sciences.

[71]  Young-Sang Jung,et al.  Peptide switch is essential for Sirt1 deacetylase activity. , 2011, Molecular cell.

[72]  Jeong Hoon Kim,et al.  Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor α activity and co-activator synergy , 2011, Nucleic acids research.

[73]  Byoung Kil Lee,et al.  Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. , 2011, Human pathology.

[74]  Roland L. Dunbrack,et al.  PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. , 2010, Biochimica et biophysica acta.

[75]  N. Kim,et al.  DBC-1 mediates endocrine resistant breast cancer cell survival , 2010, Cell Cycle.

[76]  H. Fukuhara,et al.  Identification of DBC1 as a transcriptional repressor for BRCA1 , 2010, British Journal of Cancer.

[77]  H. Fukuhara,et al.  Repression of estrogen receptor beta function by putative tumor suppressor DBC1. , 2010, Biochemical and biophysical research communications.

[78]  S. Grossman,et al.  CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53 , 2009, Proceedings of the National Academy of Sciences.

[79]  Junjie Chen,et al.  p30 DBC is a potential regulator of tumorigenesis , 2009, Cell cycle.

[80]  Yu Xue,et al.  DOG 1.0: illustrator of protein domain structures , 2009, Cell Research.

[81]  L. Aravind,et al.  Analysis of DBC1 and its homologs suggests a potential mechanism for regulation of Sirtuin domain deacetylases by NAD metabolites , 2008, Cell cycle.

[82]  Junjie Chen,et al.  DBC1 is a negative regulator of SIRT1 , 2008, Nature.

[83]  J. Qin,et al.  Negative regulation of the deacetylase SIRT1 by DBC1 , 2008, Nature.

[84]  D. Reinberg,et al.  SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation , 2007, Nature.

[85]  N. Kim,et al.  Modulation of estrogen receptor α protein level and survival function by DBC-1 , 2007 .

[86]  C. Glass,et al.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. , 2006, Genes & development.

[87]  E. White,et al.  Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling , 2005, Oncogene.

[88]  R. Roeder,et al.  Regulation of the p300 HAT domain via a novel activation loop , 2004, Nature Structural &Molecular Biology.

[89]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[90]  T. Walsh,et al.  DBC2, a candidate for a tumor suppressor gene involved in breast cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  L. Zannini,et al.  Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology. , 2018, Mutation research.

[92]  D. Delia,et al.  Chk2 and REG (cid:2) -dependent DBC1 regulation in DNA damage induced apoptosis , 2014 .

[93]  A. McLennan,et al.  The Nudix hydrolase superfamily , 2005, Cellular and Molecular Life Sciences CMLS.